Skip to main content Accessibility help
×
Home
Hostname: page-component-99c86f546-t82dr Total loading time: 1.083 Render date: 2021-12-02T08:29:03.591Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

Chapter 24 - Selective Estrogen Receptor Modulators (SERMs) and Menopausal Hormone Therapy (MHT)

Published online by Cambridge University Press:  18 June 2020

Nicholas Panay
Affiliation:
Queen Charlotte's & Chelsea Hospital, London
Paula Briggs
Affiliation:
Liverpool Women's NHS Foundation Trust
Gabor T. Kovacs
Affiliation:
Monash University, Victoria
Get access

Summary

SERMs (selective estrogen receptor modulators) are unique synthetic compounds that bind to the estrogen receptor and, depending on their unique conformational change, will either initiate estrogen agonistic activity or antagonistic activity. There are many that have come to market and others that have not. The first, for all practical purposes, was tamoxifen (although, clomiphene citrate is often considered a SERM). Approved in the US for treatment of breast cancer in 1978, tamoxifen became the most widely prescribed anti-cancer drug worldwide. When news of its ability to cause a small number of endometrial carcinomas surfaced, there was renewed interest in the SERM raloxifene, whose preclinical work suggested that, in experimental animals, it behaved differently in the uterus. In the US, Raloxifene was approved for prevention of osteoporosis in 1997, treatment of osteoporosis in 1999, and breast cancer risk reduction in 2009. Tamoxifen is also currently approved for breast cancer risk reduction.

Type
Chapter
Information
Managing the Menopause , pp. 246 - 253
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wilson, JD, Lee, RA, Balen, AH, Rutherford, AJ. Bacterial vaginal flora in relation to changing oestrogen levels. Int J STD AIDS 2007;18(5):308–11.CrossRefGoogle ScholarPubMed
Parish, SJ, Nappi, RE, Krychman, ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvo-vaginal atrophy. Int J Womens Health 2013;5:437–47.Google Scholar
Crandall, CJ, Hovey, KM, Andrews, CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause 2018;25(1):1120.CrossRefGoogle ScholarPubMed
Kingsberg, SA, Krychman, M, Graham, S, et al. The Women’s EMPOWER Survey: identifying women’s perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med 2017;14(3):413–24.CrossRefGoogle ScholarPubMed
Berga, SL. Profile of ospemifene in the breast. Reprod Sci 2013;20(10):1130–6.CrossRefGoogle ScholarPubMed
Bachmann, GA, Komi, JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17(3):480–6.Google ScholarPubMed
Portman, DJ, Bachmann, GA, Simon, JA, Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20(6):623–30.Google ScholarPubMed
Archer, DF, Goldstein, SR, Simon, JA, Waldbaum, AS, Sussman, SA, Altomare, C, Zhu, J, Yoshida, Y, Schaffer, S, Soulban, G. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause 2019;26(6):611–21.Google ScholarPubMed
ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014;123(1):202–16.Google Scholar
Osphena [package insert]. 2018. Shionogi Inc.Google Scholar
Ospemifene (Osphena) for dyspareunia. Med Lett Drugs Ther 2013;55(1420):55–6.Google Scholar
Addendum: Ospemifene (Osphena) for dyspareunia (Med Lett Drugs Ther 2013;55:55). Med Lett Drugs Ther 2013;55(1427):84.Google Scholar
Goldstein, SR, Bachmann, G, Lin, V, et al. Endometrial safety profile of ospemifene 60 mg when used for long-term treatment of vulvar and vaginal atrophy for up to 1 year [abstract]. Climacteric 2011;14 Suppl 1:S57.Google Scholar
Goldstein, SR, Scheele, WH, Rajagopalan, SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95(1):95103.Google ScholarPubMed
Qu, Q, Zheng, H, Dahllund, J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141(2):809–20.CrossRefGoogle Scholar
Eigeliene, N, Kangas, L, Hellmer, C, et al. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause 2016;23(7):719–30.Google ScholarPubMed
Kangas, L, Unkila, M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids 2013;78(12–13):1273–80.CrossRefGoogle ScholarPubMed
Constantine, GD, Kagan, R, Miller, PD. Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women. Menopause 2016;23(6):638–44.Google Scholar
Gerdhem, P, Ivaska, KK, Alatalo, SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19(3):386–93.Google ScholarPubMed
Schiavi, MC, Zullo, MA, Faiano, P, et al. Retrospective analysis in 46 women with vulvovaginal treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol 2017;33(12):942–5.CrossRefGoogle ScholarPubMed
Schiavi, MC, Di Pinto, A, Sciuga, V, et al. Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene. Gynecol Endocrinol 2018;34(2):140–3.CrossRefGoogle ScholarPubMed
Brostrøm, S, Lose, G. Oestrogen for prevention of recurrent urinary tract infections in postmenopausal women – a survey of a Cochrane review [in Danish]. Ugeskr Laeger 2009;171(36):2568–71.Google ScholarPubMed
Unni, S, Yao, Y, Milne, N, et al. An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record database. Osteoporos Int 2015;26:581–7.CrossRefGoogle ScholarPubMed
Silverman, SL, Kupperman, ES, Bukata, SV, Members of IOFFWG. Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group. Osteoporos Int 2016;27:2197–206.CrossRefGoogle ScholarPubMed
Silverman, SL, Chines, AA, Kendler, DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23:351–63.CrossRefGoogle ScholarPubMed
de Villiers, TJ, Chines, AA, Palacios, S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011;22:567–76.CrossRefGoogle ScholarPubMed
Silverman, SL, Christiansen, C, Genant, HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923–34.CrossRefGoogle ScholarPubMed
Peng, L, Luo, Q, Lu, H. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Medicine 2017;96(49):e8659.CrossRefGoogle ScholarPubMed
Komm, BS, Mirkin, S. Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. Int J Womens Health 2012;4:129–40.Google ScholarPubMed
Anderson, GL, Chlebowski, RT, Aragaki, AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative Randomized Trial. Lancet Oncol 2012;13:476–86.CrossRefGoogle Scholar
Manson, JE, Aragaki, AK, Rossouw, JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative Randomized Trials. JAMA 2017;318:927–38.CrossRefGoogle ScholarPubMed
Ronkin, S, Notthington, R, Baracat, E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397–404.CrossRefGoogle ScholarPubMed
Kharode, Y, Bodine, PV, Miller, CP, Lyttle, CR, Komm, BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084–91.CrossRefGoogle ScholarPubMed
Song, Y, Santen, RJ, Wang, JP, Yue, W. Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. Endocrinology 2012;153:5706–15.CrossRefGoogle ScholarPubMed
Umland, EM, Karel, L, Santoro, N, et al. Bazedoxifene and conjugated equine estrogen: a combination product for the management of vasomotor symptoms and osteoporosis prevention associated with menopause. Pharmacotherapy 2016;36:548–61.CrossRefGoogle ScholarPubMed
Pinkerton, JV, Utian, WH, Constantine, G, Oliver, S, Pickar, JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–24.Google ScholarPubMed
Lindsay, R, Gallagher, JC, Kagan, R, Pickar, JH, Constatine, G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52.CrossRefGoogle ScholarPubMed
Kagan, R, Goldstein, SR, Pickar, JH, Komm, BS. Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene. Ther Clin Risk Manag 2016;12:549–62.Google ScholarPubMed
Komm, BS, Mirkin, S, Jenkins, SN. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Steroids 2014;90:7181.CrossRefGoogle ScholarPubMed
Mirkin, S, Pinkerton, JV, Kagan, R, et al. Gynecologic safety of conjugated estrogens plus bazedoxifene: pooled analysis of five Phase 3 trials. J Women’s Health 2016;25:431–42.CrossRefGoogle ScholarPubMed
Pinkerton, JV, Harvey, JA, Pan, K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013;121:959–68.CrossRefGoogle ScholarPubMed
Stovall, DW, Utian, WH, Gass, MLS, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510–17.Google ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats
×

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats
×